Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmutepIMMP -1.81%23 Days Sales Outstanding is 0.00 as of Mar. 2026. GuruFocus rates IMMP with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 840 Biotechnology companies, Immutep ranks worse than 119047.5% on this metric.
Immutep's average Accounts Receivable for the
three
months ended in Mar. 2026 was $19.87 Mil. Immutep's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil.
The historical rank and industry rank for Immutep's Days Sales Outstanding or its related term are showing as below:
During the past 13 years, Immutep's highest Days Sales Outstanding was 10672.34. The lowest was 73.00. And the median was 286.37.
IMMP's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 69.09 * Ranked among companies with meaningful Days Sales Outstanding only.
Immutep's Days Sales Outstanding
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
Immutep (NAS:IMMP) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Immutep Days Sales Outstanding Related Terms
Immutep Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Immutep's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMMP vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Immutep's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immutep Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immutep's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Immutep's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immutep (IMMP) has a Days Sales Outstanding of 0.00 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Immutep and its competitors. Over the past decade, Immutep's Days Sales Outstanding has ranged from 73.00 to 10,672.34. According to the industry distribution chart, Immutep ranks #999999 out of 840 companies in the Biotechnology industry.
Is Immutep's Days Sales Outstanding too high?
Immutep's current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 73.00 to a high of 10,672.34. Based on the distribution chart, Immutep ranks #999999 out of 840 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immutep has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Immutep's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immutep ranks #999999 out of 840 companies for Days Sales Outstanding. This places Immutep in the lower half of its industry. The industry median Days Sales Outstanding is 69.09. Historically, Immutep's own Days Sales Outstanding has ranged from 73.00 to 10,672.34 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.09, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Immutep and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immutep's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immutep stock overvalued right now?
Immutep (IMMP) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. Immutep's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Immutep (IMMP), the current Days Sales Outstanding is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
23GF Score
Get the complete analysis for IMMP
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMMP has been successfully added to your 
